SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as community members discuss potential partnerships, including speculation around Apple and TSMC, and the impact of government investment in domestic chip manufacturing. Bullish sentiment is fueled by the possibility of Intel becoming a key player in the U.S. semiconductor industry. Some traders are also discussing short positions and potential pullbacks after the recent price increase.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is experiencing heightened interest, possibly due to its privacy features and upcoming halving event, with some community members drawing comparisons to Bitcoin's early days and anticipating significant price appreciation. Community discussions revolve around price targets and the potential for Zcash to outperform other cryptocurrencies. Zcash's focus on shielded transactions is also seen as a key differentiator in a world increasingly concerned about financial privacy.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around the meme-based token on the Solana network. Community members are actively sharing the token's contract address and encouraging others to swap $SOL for $UPDOG on $JUP.X. The coin has been live for over a year and the community is constantly asking each other the age old question, 'What's UpDog?'

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial data for its skin drug, sonelokimab, sparking buyout speculation and excitement among retail investors. The community is actively discussing the potential for larger gains and debating the market's reaction to the news, with some cautioning about a possible "sell the news" event. Trading halts and order rejections are also being noted.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the crypto community debates its short-term trajectory, with some anticipating a continued climb towards new highs fueled by bullish technical indicators like double bottom formations on the 20-week EMA and institutions reporting even more ownership after buying OTC. Others remain cautious, citing potential weekend bull traps and the possibility of a pullback to lower support levels, sparking discussions on market manipulation and the influence of major players like Michael Saylor.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as community members discuss Cigna adding Auvelity to its preferred drug list in 2026, potentially setting a precedent for other insurers. Sponsorship of educational events and analysis of prescription data are also fueling conversation. Despite some concerns regarding share sales and pipeline candidates, many remain optimistic about Axsome's growth trajectory and potential FDA approvals.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending following the announcement of a significant private placement, with community members discussing key support and resistance levels to watch. Some traders are pointing to the potential for dilution due to warrants included in the deal. Others are optimistic about continued momentum given the tight float and recent after-hours spike.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is trending amid bullish sentiment surrounding nuclear energy and discussions of potential policy tailwinds. Community members are actively discussing entry points, price targets, and the company's potential to benefit from increased demand driven by AI and data centers. Some traders are also noting unusual options activity and technical patterns, while others debate the company's valuation and production capabilities relative to its peers.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending due to community excitement surrounding its Nasdaq uplisting and potential exposure to a broader investor base. Discussions revolve around the company's focus on post-quantum cryptography and its potential role in securing digital assets, with some anticipating significant growth and institutional interest. Some investors are concerned about potential dilution following the uplisting.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CRWV is trending amidst discussions around its AI infrastructure and recent deals, including a significant expansion with OpenAI. Community members are actively debating the stock's valuation, potential for dilution, and its relationship with NVIDIA, with some expressing concerns about high debt levels and insider selling, while others highlight strong growth prospects and potential for a squeeze.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anavex Life Sciences Corp. (AVXL) on Tuesday announced that its experimental Alzheimer’s drug demonstrated cognitive stabilization in patients with early Alzheimer’s disease in a study.After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine in a precision medicine population demonstrated barely detectable cognitive decline on all standard scales for measuring cognitive decline, comparable to the minimal decline in pre-dementia aging adults.Shares of the company rose 2% on Tuesday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-announces-oral-blarcamesine-cognitive-resilience-results-approximating-normal-a">said</a> that the drug caused about an 84.7% reduction in cognitive decline as compared to placebo on a standardized neuropsychological test used in Alzheimer's disease research to measure cognitive function.“Today’s new clinical efficacy data update from our Phase IIb/III trial is critical, as it adds contemporary context to Precision Medicine data showing strong protection from Alzheimer’s disease with an oral once-daily potential solution with the aim to alleviate significant medical and economic burden,” said Juan Carlos Lopez-Talavera, Head of Research and Development of Anavex.Anavex will continue to evaluate trial data, which will be published and presented at international conferences, the company said.Anavex is also studying Blarcamesine, its lead candidate, in dementia caused by Parkinson's disease, a neurodegenerative brain condition, and in patients with Rett syndrome, a rare genetic neurological and developmental disorder that affects the way the brain develops.AVXL stock is down 12% this year but up approximately 84% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-1.5-million-vehicles-in-us/chwKduPRdte">Ford Draws Retail Investor Concerns After It Recalls Nearly 1.5M Vehicles In US Over Rear View Camera Display Issues</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study

After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said. 

Equity

After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said. 


Anavex Life Sciences slipped in after-hours trading on Monday after the company said it plans to raise&nbsp;as much as $300 million by selling shares.The stock closed at $11.48 on Monday, up 3.3% for the day, before slipping 1% to $11.37 in after-hours trading.The stock offering comes on the heels of its latest quarterly results,&nbsp;which showed net loss was $11.2 million, or $0.13 a share, compared with a loss of $10.5 million in the same period last year.&nbsp;The company had $115.8 million in cash at the end of March and said that it would fund the company for about four years.In April, Anavex disclosed an update on the long-term data on its Alzheimer’s candidate, blarcamesine. According to new data released, the drug slowed cognitive decline in early-stage Alzheimer’s patients over&nbsp;four years.&nbsp;The results were disclosed at the AD/PD 2025 conference, and they hint that the treatment may have a disease-modifying effect if started early and taken continuously.The drug has also been well tolerated. No&nbsp;significant safety issues were reported, and dizziness, the most common side effect, was reduced by tweaking the dose schedule.Anavex has also wrapped up enrollment for a mid-stage trial of its schizophrenia drug, Anavex 3-71, with results expected in the second half of the year.&nbsp;Separately, 74 patients remain on long-term blarcamesine therapy through a Compassionate Use Program, with some having taken the drug daily for over nine years.On Stocktwits, retail sentiment for Anavex was ‘extremely bullish’ amid ‘high’ message volume.One user viewed the shelf registration as a bullish signal, suggesting that Anavex may be positioning itself for a potential EMA approval.&nbsp;They speculated the filing could be tied to plans for standalone distribution or as a strategic move to strengthen the company’s hand in partnership talks, calling it “nothing but good news” for long-term holders.<stembedurl>https://stocktwits.com/PartyNaked/message/620947957</stembedurl>Another user said that the S-3 filing doesn’t mean an immediate offering, but rather gives the company flexibility to raise funds if needed, particularly after a major catalyst like an EMA decision.&nbsp;They called the move smart and standard for biotech firms, arguing it allows Anavex to act quickly if the stock jumps post-approval and strengthens its negotiating position with potential partners.<stembedurl>https://stocktwits.com/kay91667/message/620942567</stembedurl>Anavex’s stock has declined 5.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avanex Life Sciences (AVXL) said it plans to raise up to $300 million by selling shares. (Photo credit: Getty Images)

Anavex Life Sciences Stock Falls After Hours On $300M Raise Plan; Retail Traders Think It’s A ‘Smart’ Move 

The after-hours move followed Anavex’s recent completion of enrollment for a mid-stage schizophrenia trial, with top-line results expected later this year. 

Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Medical Stocks Lagging  Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday. The stocks trending the most on the Stocktwits platform include Webull, SharpLink, Anavex Life Sciences, BigBear.ai, and Oscar Health.1. Webull Corp. (BULL)<img src="https://news.stocktwits-cdn.com/BULL_png_3a86d4a0fc.webp" alt="BULL.png">2. SharpLink Gaming Ltd. (SBET)<img src="https://news.stocktwits-cdn.com/SBET_png_ddf51dbef1.webp" alt="SBET.png">3. Anavex Life Sciences Corp. (AVXL)<img src="https://news.stocktwits-cdn.com/AVXL_png_b962881047.webp" alt="AVXL.png">4. BigBear.ai Holdings Inc. (BBAI)<img src="https://news.stocktwits-cdn.com/BBAI_png_3156927dd7.webp" alt="BBAI.png">5. Oscar Health Inc. (OSCR)<img src="https://news.stocktwits-cdn.com/OSCR_png_e8f637dd66.webp" alt="OSCR.png">Disclaimer: Stocktwits' "Why It's Trending" summary is AI-generated and may contain errors.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-us-make-fortune-if-big-beautiful-bill-is-passed-but-house-republicans-could-sink-it/chF0ot3RTyE">Trump Says US Will ‘Make A Fortune’ If The Big Beautiful Bill Is Passed, But House Republicans Could Sink It</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 06, 2024 in New York City as the market opened after the worst crash since 2022

Top 5 Trending Stocks On Stocktwits Today: Webull, SharpLink, Anavex Life Sciences, BigBear.ai, And Oscar Health

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday.

Lightning Round: Sell Viking Therapeutics, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, Transocean, and DuPont...

Anavex Life Sciences Corp., a small-cap biotech specializing in neurodegenerative and neurodevelopmental diseases, emerged as the top pick among retail investors in a recent Stocktwits poll.&nbsp;Nearly 45% of respondents believe Anavex will outperform in the first quarter of 2025, compared to 33% for Novavax and 9% for Rigel Pharmaceuticals.<stembedurl>https://stocktwits.com/StocktwitsPolls/message/599783274</stembedurl>Alzheimer’s Therapy MomentumAnavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73), whose European Marketing Authorization Application was&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/avxl-stock-rises-on-q4-results-ema-nod-for-blarcamesine/cJazDmdRj5">accepted</a> last month.&nbsp;Promising trial results showed three years of continuous blarcamesine treatment significantly reduced clinical decline in early Alzheimer’s patients, with no safety issues reported.&nbsp;That positions the drug as a potential breakthrough, especially as interest in Alzheimer’s therapies intensifies following recent setbacks for rivals like Cassava Sciences.The company’s stock surged over 76% in 2024 but is down 6% year-to-date, with a high short interest of 24.5% as per Koyfin data.&nbsp;Anavex reported $132.2 million in cash reserves as of Sept. 30, 2024, and projects a four-year cash runway at its current burn rate.Vaccine Maker Eyes RecoveryNovavax has maintained momentum after a 68% gain in 2024, with shares up nearly 6% this year.&nbsp;The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvax-stock-is-undervalued-say-retail-investors/chGWtkSRZy">recovered</a> from an FDA clinical hold on its COVID-19 and flu combination vaccine late last year, thanks to a $50 million milestone payment under its Sanofi partnership and increasing hopes for a bird flu vaccine.&nbsp;Novavax holds the largest market cap among the three at $1.38 billion. It has $909.5 million in cash and a manageable debt load of $262 million, which many retail investors see as an advantage.&nbsp;It also has a high short interest of 24.5%.Under-The-Radar Bet?Rigel Pharmaceuticals focuses on autoimmune and hematologic diseases. The company recently received orphan drug designation for R289, a treatment for lower-risk myelodysplastic syndromes.&nbsp;A growing portfolio of approved therapies, such as TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for acute myeloid leukemia has also boosted retail sentiment.On Monday, the company said it expects fourth-quarter revenue of $57.6 million, up 61% year-over-year and above a Wall Street estimate of $47.4 million. It also projected 2025 revenue of $200-$210 million, better than an expected $193.5 million.Rigel’s stock rose 15% in 2024 and remained nearly flat in 2025. As of Dec. 31, 2024, it had estimated cash reserves of $77.3 million.&nbsp;Rigel’s short interest is relatively low at 3.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Anavex has garnered attention for its investigational Alzheimer’s drug, blarcamesine (ANAVEX 2-73). | Image source: Getty Images 

Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.

Anavex Life Sciences Corp. shares rocketed over 27% on Monday, hitting their highest levels since February 2023, fueled by a mix of positive earnings results and regulatory progress in Europe.The biopharma company, focused on neurodegenerative and neurodevelopmental diseases, reported a fiscal fourth-quarter loss of $11.6 million, or an adjusted $0.14 per share, compared to a loss of $10.1 million in the year-ago period.&nbsp;While research and development (R&amp;D) and overhead costs rose, the per-share loss was narrower than the FactSet consensus estimate of $0.16.Anavex also highlighted a strong cash position, with $132.2 million in reserves, which the company says will provide a four-year runway at current burn rates.Creating more buzz was news that the European Medicines Agency (EMA) accepted the Marketing Authorization Application for blarcamesine (ANAVEX 2-73), an investigational oral drug for Alzheimer’s disease.&nbsp;Anavex’s Head of R&amp;D, Juan Carlos Lopez-Talavera, said: "The EMA filing acceptance for blarcamesine to review the Marketing Authorization Application potentially brings us a step closer offering broader patient access to a new treatment option in Europe, and we look forward to continued engagement with the EMA.”CEO Christoper Missling said, "We are excited about the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing and our team remains deeply committed to executing on our momentum.”<figure class="image"><img style="aspect-ratio:1326/1056;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_poll_sentiment_and_message_volume_Dec_24_fe40cd4f12.png" alt="AVXL poll sentiment and message volume Dec 24.png" width="1326" height="1056"><figcaption>AVXL poll, sentiment and message volume on Dec 24 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits celebrated the news, with sentiment shifting sharply to ‘bullish’ from ‘neutral.’&nbsp;Many hailed the EMA filing as a significant milestone, with one user claiming very high approval rates by the European regulator for “accepted drug candidates in 2024 that aren't withdrawn.”<stembedurl>https://stocktwits.com/Guzzi62/message/597573043</stembedurl><stembedurl>https://stocktwits.com/PhillipHerass/message/597572113</stembedurl><stembedurl>https://stocktwits.com/Logic102/message/597572650</stembedurl>According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10499418/">study</a> published last year in the Clinical and Translational Science, an official journal of the American Society for Clinical Pharmacology and Therapeutics, the EMA was found to have the highest approval rate (93.8%) for non-oncology products when compared with Swiss and U.S. regulators. The data analyzed decisions between 2009 and 2018 on new active substances.The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sava-stock-plunges-after-alzheimers-trial-fails/cJIf1KdRgh">reported</a> disappointing results for its candidate simufilam last month.&nbsp;D. Boral Capital had noted Anavex’s neuroprotective mechanism could position blarcamesine as a superior option, reiterating a ‘Buy’ rating with a $46 price target.Anavex shares are now up 88% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

EMA European Medicines Agency at Canary Wharf on 5th November 2024 in London, United Kingdom. (photo by Mike Kemp/In Pictures via Getty Images)

Anavex Sciences Soars On Earnings Relief, EU Filing Acceptance For Alzheimer’s Drug: Retail’s Overjoyed

The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences reported disappointing results for its candidate simufilam last month.

What To Expect in the Markets This Week

Coming up: Shortened market hours around the Christmas holiday, consumer confidence, new home sales, initial jobless claimsGetty ImagesKey TakeawaysMarkets are closed Wednesday for Christmas.On...

This Week’s Hottest Themes: Biotech (RFK Jr. Meddling), Space (Trump's Space Force),&nbsp; AI (The Theme of the Year)&nbsp;WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in sectors actively drawing capital. This targeted approach, combined with real-time news surveillance, helps us uncover stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.Here's a list of today's most important names:1. Cassava Sciences (NASDAQ: SAVA)Background: Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer’s disease. Its investigational drug, Simufilam, has been central to its research efforts.The News: Cassava's stock took a dramatic plunge after disappointing Phase 3 trial results for Simufilam, followed by a social media storm triggered by Martin Shkreli’s scathing critique of the drug’s efficacy. Shkreli, calling Simufilam’s mechanism “implausible,” encouraged short-sellers, predicting a sharp decline in the stock. The failure of the trial and Shkreli’s influence sent shares tumbling by more than 85%, from nearly $30 per share to under $5.What It Means: This setback emphasizes the significant risks in Alzheimer's drug development. With most Alzheimer’s trials failing, investors now question the credibility of Cassava’s lead drug. While the company still has resources to pivot, the stock’s credibility has been deeply shaken, and the road ahead is uncertain.Stock Reaction: Yesterday the stock opened at $30 but closed near $5, reflecting a swift and steep sell-off. The market’s reaction shows how quickly investor sentiment can turn negative on biotech stocks, particularly in high-risk, high-reward sectors like Alzheimer’s treatment.&nbsp;2. Poseida Therapeutics (NASDAQ: PSTX)Background: Poseida is a biopharmaceutical company specializing in gene therapies, particularly CAR-T treatments for cancer.The News: Poseida announced a significant partnership with Roche, securing $110 million upfront and up to $1 billion in potential milestones. This deal is aimed at accelerating Poseida's CAR-T therapies and other cell and gene therapy technologies.What It Means: This collaboration is a major validation for Poseida’s technology, especially in the competitive CAR-T space, which has attracted attention due to its potential to treat cancers. The cash infusion from Roche is expected to fuel further research and development.Stock Reaction: Poseida opened at $9.26, up over 200%, rising slightly to close at $9.38. The market responded favorably to the news, viewing the Roche deal as a solid indication of Poseida’s future potential in the cancer treatment landscape.&nbsp;3. KULR Technology Group (NYSE: KULR)Background: KULR specializes in thermal management technologies for energy storage and aerospace.The News: KULR Technology Group has received a U.S. Navy contract to develop its Internal Short Circuit (ISC) technology to operate at higher temperatures. This upgrade is important for both military and commercial applications, especially in aviation where it aligns with safety standards. The ISC devices, originally developed with NASA and NREL, simulate controlled thermal runaway in lithium-ion cells for more accurate and safer testing of battery behavior in extreme conditions.What It Means: The Navy contract could serve as a major stepping stone for KULR, providing the company with exposure to one of the most demanding industries for thermal solutions. This deal not only enhances KULR’s credibility but may also open doors for similar partnerships in the aerospace and defense sectors.Stock Reaction: The stock opened at $0.80 and climbed another 20% reaching $0.96 by mid-morning on volume that is 1,000%+ higher than average.&nbsp;4. POET Technologies (NASDAQ: POET)Background: POET is a leader in photonics technology, designing advanced semiconductor solutions aimed at AI, telecommunications, and data storage.The News: POET Technologies (NASDAQ: POET) is ramping up production of its optical engines to meet the increasing demand from AI applications. A recent report highlighted that while many companies in the UK are adopting AI, few have integrated it into their manufacturing processes, which could hinder innovation and productivity. The report suggests that government support and regulations could help accelerate AI adoption in industries.What It Means: As AI applications continue to expand, POET’s new platform could be a game-changer. The optical interposer aims to address the bottlenecks in data processing by enabling faster, more efficient communication between chips, which is crucial for AI and big data.Stock Reaction: POET opened at $4.38 and rose to $5.35 (up 22%) by mid-day on volume 3x higher than average.&nbsp;5. SurgePays (NASDAQ: SURG)Background: SurgePays provides financial services and prepaid wireless solutions for underserved markets.The News:&nbsp;SurgePays (SURG) has integrated its ClearLine marketing platform with PAX smart payment terminals, allowing merchants to deliver real-time promotions and offers during transactions. This integration leverages existing hardware to enhance customer engagement and streamline marketing efforts, helping retailers boost loyalty and sales. SurgePays aims to scale its retail presence by utilizing PAX's wide reach in the payment terminal industry.What It Means: SurgePays continues to capitalize on the significant need for affordable financial services and wireless solutions in underserved communities. This strong performance suggests the company’s business model is scaling effectively, positioning it well for future growth.Stock Reaction: SurgePays opened at $2.00 and surged to $2.20, up 10%, trading average volume.&nbsp;6. TOYO Ventures Holdings (NASDAQ: TOYO)Background: TOYO Co., Ltd. is a solar solutions company focused on becoming a full-service provider in the global market. It integrates all stages of the solar power supply chain, including wafer and silicon production, solar cell manufacturing, and photovoltaic module production. TOYO is positioned to produce high-quality solar cells at a competitive scale and cost.The News: TOYO Co., Ltd (Nasdaq: TOYO) has secured a $150 million contract to supply high-efficiency solar cells to a major solar module manufacturer. The agreement will support solar module production in India and the U.S., leveraging TOYO’s advanced manufacturing capabilities in Vietnam and Ethiopia. This contract highlights the company's commitment to sustainable energy and the global shift towards renewable resources.What It Means: The $150 million contract is a major win for TOYO Co., Ltd, solidifying its role as a key player in the solar energy sector. It highlights the company’s advanced manufacturing capabilities and global reach, particularly in India and the U.S. For the market, the deal signals continued growth in the solar industry, boosting confidence in renewable energy technologies and potentially attracting more investment. TOYO’s expanded presence in key markets could strengthen its competitive position as demand for efficient solar cells rises..Stock Reaction: Shares opened at $5.56, up 39% to retrace to $4.50 by mid-morning and closing at $5.41 on eye-poping 1,500x average volume.&nbsp;&nbsp;7. Anavex Life Sciences (NASDAQ: AVXL)Background:&nbsp;Anavex Life Sciences develops treatments for neurodegenerative disorders like Alzheimer's and Parkinson's. Its lead drug, ANAVEX®2-73, has shown positive results in Phase 2 trials, while the company is also developing ANAVEX®3-71 for Alzheimer's.The News:Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug, blarcamesine (ANAVEX®2-73), to the European Medicines Agency (EMA) for the treatment of Alzheimer’s disease. Blarcamesine, an orally administered small molecule, showed significant clinical improvement in patients over 48 weeks, with better efficacy than approved therapies and a slower rate of neurodegeneration in early Alzheimer's patients. Its safety profile eliminates the need for routine MRI monitoring, making it a promising treatment option.What It Means:&nbsp;The MAA submission for blarcamesine to the EMA is a positive development for Anavex Life Sciences, potentially boosting its stock if approved. If successful, blarcamesine could open new revenue streams and strengthen investor confidence. For the broader market, this signals progress in Alzheimer’s treatment, potentially drawing more investment into biotech, especially in neurodegenerative diseases.Stock Reaction: Anavex opened at $10.30 up 10% from Monday's close, but cratered almost 20% from that high by mid-afternoon closing nearly flat from the previous day's close on slightly higher than average volume.&nbsp;&nbsp;Be The First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST&nbsp;SpaceMobile (NASDAQ: ASTS) which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;&nbsp;<hr>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WealthyVC">Follow us on Twitter</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/wealthyventurecapital/">Follow us on Instagram</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/TheWealthyVentureCapitalist/?locale=zh_CN">Follow us on Facebook</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVXL News

AVXL Anavex Life Sciences Corp